Literature DB >> 9679974

Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.

P Jantzer1, D J Schendel.   

Abstract

Renal cell carcinomas (RCCs) are thought to be immunogenic, because cytokine-induced and even spontaneous tumor regression has been observed in a significant number of patients. However, little is known about the nature of immune responses that might lead to tumor regression. We studied naturally arising human T-cell responses against RCC by combining molecular analyses of T-cell receptor (TCR) usage in primary tumors in situ with functional analyses of tumor-infiltrating lymphocytes (TILs) in vitro. TILs of patient 26 that were cultured in vitro showed a human leukocyte antigen (HLA-A*0201)-restricted cytotoxic activity specific for autologous tumor cells. These tumor-derived lymphocytes were dominated by a family of T cells expressing V alpha20- and V beta22-positive TCRs. Their specificity-conferring third complementarity-determining regions were highly homologous with respect to the loop length and selection of particular amino acids in both TCR chains. These characteristics are similar to those reported for antigen-selected murine T cells recognizing immunodominant epitopes of non-self proteins. To evaluate the biological significance of these CTLs in vivo, we analyzed the corresponding TCR transcripts in the cryopreserved tumor material of patient 26 and in a second HLA-A*0201-positive RCC patient whose tumor cells were also lysed by TIL-26. The in situ TIL populations of both patients used related families of highly homologous TCRs, supporting the contention that immunodominant responses directed against a shared tumor-associated antigen occurred in both individuals in vivo. Furthermore, in the absence of overt metastatic disease, the tumor antigen-specific CTLs of patient 26 were shown to persist in the periphery 4 years after removal of the primary tumor. These results demonstrate that antigen-driven T-cell responses specific for spontaneously arising carcinomas developed in these patients and showed long-term persistence, even in the absence of immunotherapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9679974

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Authors:  Bernhard Frankenberger; Sybille Regn; Christiane Geiger; Elfriede Noessner; Christine S Falk; Heike Pohla; Miran Javorovic; Tobias Silberzahn; Susanne Wilde; Alexander Buchner; Michael Siebels; Ralph Oberneder; Gerald Willimsky; Antonio Pezzutto; Thomas Blankenstein; Dolores J Schendel
Journal:  World J Urol       Date:  2005-07-05       Impact factor: 4.226

Review 3.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.

Authors:  Scott S Tykodi; Brenda M Sandmaier; Edus H Warren; John A Thompson
Journal:  Expert Opin Biol Ther       Date:  2011-03-21       Impact factor: 4.388

4.  Prognostic histological and immune markers of renal cell carcinoma.

Authors:  T Magyarlaki; I Buzogány; L Kaiser; F Sükösd; R Döbrönte; B Simon; A Fazekas; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

5.  Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.

Authors:  T Magyarlaki; I Buzogány; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

6.  Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Authors:  Thomas Schwaab; Adrian Schwarzer; Benita Wolf; Todd S Crocenzi; John D Seigne; Nancy A Crosby; Bernard F Cole; Jan L Fisher; Jill C Uhlenhake; Diane Mellinger; Cathy Foster; Zbigniew M Szczepiorkowski; Susan M Webber; Alan R Schned; Robert D Harris; Richard J Barth; John A Heaney; Randolph J Noelle; Marc S Ernstoff
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

Review 7.  B7-H1 pathway and its role in the evasion of tumor immunity.

Authors:  Haidong Dong; Lieping Chen
Journal:  J Mol Med (Berl)       Date:  2003-04-30       Impact factor: 4.599

Review 8.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 9.  Oligoclonal T cells in human cancer.

Authors:  E Halapi
Journal:  Med Oncol       Date:  1998-12       Impact factor: 3.064

Review 10.  Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors.

Authors:  Matthew F Mescher; Flavia E Popescu; Michael Gerner; Chris D Hammerbeck; Julie M Curtsinger
Journal:  Semin Cancer Biol       Date:  2007-06-23       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.